These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27697544)

  • 1. Gadolinium deposition: Is it chelated or dissociated gadolinium? How can we tell?
    Tweedle MF
    Magn Reson Imaging; 2016 Dec; 34(10):1377-1382. PubMed ID: 27697544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatially resolved quantification of gadolinium deposited in the brain of a patient treated with gadolinium-based contrast agents.
    Fingerhut S; Niehoff AC; Sperling M; Jeibmann A; Paulus W; Niederstadt T; Allkemper T; Heindel W; Holling M; Karst U
    J Trace Elem Med Biol; 2018 Jan; 45():125-130. PubMed ID: 29173468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy.
    Prybylski JP; Semelka RC; Jay M
    Magn Reson Imaging; 2016 Dec; 34(10):1391-1393. PubMed ID: 27530538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium tissue deposition in brain and bone.
    Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
    Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of gadolinium(III) complexes in biological tissue extracts.
    Kahakachchi CL; Moore DA
    Metallomics; 2010 Jul; 2(7):490-7. PubMed ID: 21072349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and quantification of potential metabolites of Gd-based contrast agents by electrochemistry/separations/mass spectrometry.
    Telgmann L; Faber H; Jahn S; Melles D; Simon H; Sperling M; Karst U
    J Chromatogr A; 2012 Jun; 1240():147-55. PubMed ID: 22525874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Impaired Renal Function on Gadolinium Retention After Administration of Gadolinium-Based Contrast Agents in a Mouse Model.
    Kartamihardja AA; Nakajima T; Kameo S; Koyama H; Tsushima Y
    Invest Radiol; 2016 Oct; 51(10):655-60. PubMed ID: 27299580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.
    Le Fur M; Caravan P
    Metallomics; 2019 Feb; 11(2):240-254. PubMed ID: 30516229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review.
    Telgmann L; Sperling M; Karst U
    Anal Chim Acta; 2013 Feb; 764():1-16. PubMed ID: 23374209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents.
    Rees JA; Deblonde GJ; An DD; Ansoborlo C; Gauny SS; Abergel RJ
    Sci Rep; 2018 Mar; 8(1):4419. PubMed ID: 29535330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gadolinium nanoparticles and molecular contrast agents for radiation therapy-enhancement.
    Delorme R; Taupin F; Flaender M; Ravanat JL; Champion C; Agelou M; Elleaume H
    Med Phys; 2017 Nov; 44(11):5949-5960. PubMed ID: 28886212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-based MRI contrast agent for the detection of tyrosinase.
    Seo H; Clark HA
    Analyst; 2020 Feb; 145(4):1169-1173. PubMed ID: 31872821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative.
    Robert P; Frenzel T; Factor C; Jost G; Rasschaert M; Schuetz G; Fretellier N; Boyken J; Idée JM; Pietsch H
    Invest Radiol; 2018 Sep; 53(9):499-517. PubMed ID: 29659381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
    Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
    Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Class of Smart Gadolinium Contrast Agent for Tissue pH Probing Using Magnetic Resonance Imaging.
    Mouffouk F; Serrai H; Bhaduri S; Achten R; Seyyedhamzeh M; Husain AA; Alhendal A; Zourob M
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32225079
    [No Abstract]   [Full Text] [Related]  

  • 17. Gadolinium retention in the body: what we know and what we can do.
    Tedeschi E; Caranci F; Giordano F; Angelini V; Cocozza S; Brunetti A
    Radiol Med; 2017 Aug; 122(8):589-600. PubMed ID: 28361260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier.
    Prybylski JP; Maxwell E; Coste Sanchez C; Jay M
    Magn Reson Imaging; 2016 Dec; 34(10):1366-1372. PubMed ID: 27580521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI.
    Lu ZR; Parker DL; Goodrich KC; Wang X; Dalle JG; Buswell HR
    Magn Reson Med; 2004 Jan; 51(1):27-34. PubMed ID: 14705042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium Retention and Toxicity-An Update.
    Ramalho M; Ramalho J; Burke LM; Semelka RC
    Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.